Tammy

Next Post

Nuvalent Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results | News

Tue Apr 5 , 2022
NVL-655 IND cleared by FDA, supporting planned initiation of ALKOVE-1 Phase 1/2 clinical trial in patients with ALK-positive NSCLC and other solid tumors in second quarter of 2022 Enrollment ongoing in ARROS-1 trial of NVL-520 for advanced ROS1-positive NSCLC and other solid tumors Discovery pipeline continues to advance toward two […]